UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
GC Lab Cell secures tech for Natural Killer cell-based immunotherapy
  • By Marian Chu
  • Published 2018.06.27 14:19
  • Updated 2018.06.27 14:19
  • comments 0

GC Lab Cell is making headway with developing its Natural Killer (NK) cell-based cancer therapy, buying globally exclusive rights to use a technology developed by Canadian biopharma firm Feldan Therapeutics.

GC Lab Cell said Wednesday it purchased exclusive rights to use Feldan Shuttle, a protein-based technology platform that carries proteins and genes into the cell, for applying it to NK cells.

“With the introducing this new technology, GC Lab Cell is continually securing unique technologies required to develop NK cell therapeutics,” GC Lab Cell CEO Park Dae-woo said.

GC Lab Cell CEO Park Dae-woo (third from left) and Feldan Therapeutics CEO Francois-Thomas Michaud (fourth from left) pose after the signing of the platform technology agreement.

GC Lab Cell is currently developing an NK immunotherapy MG4101, which the company claims to be the closest to commercialization worldwide. The company launched a phase 2 trial for MG4101 in Korea this year, becoming the first company to carry out a P2 test for an NK cell therapy.

“We expect this will serve as an opportunity for our technology to be applied to various next-generation immune cell therapy products,” Feldan Therapeutics CEO Francois-Thomas Michaud said.

yjc@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Marian Chu
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top